Physician profile
Jessica Jun
NPI 1265951016
$2,116.75
in general payments reported to CMS, 2019-2025
15 companies · $338 in 2025
The $338 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $24.20 · 2022: $269 · 2023: $1,038 · 2024: $447 · 2025: $338.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,823.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,823.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $396.27 | 2022-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $366.39 | 2022-2025 | Uzedy, Austedo Xr, Austedo |
| Vanda Pharmaceuticals INC. | $348.60 | 2022-2025 | Hetlioz, Fanapt |
| Alkermes, INC. | $233.03 | 2023-2025 | Aristada, Lybalvi |
| Abbvie INC. | $227.18 | 2022-2025 | |
| Idorsia Pharmaceuticals US INC | $121.87 | 2023 | Quviviq |
| Janssen Pharmaceuticals, INC | $102.37 | 2023-2024 | Spravato, Invega Sustenna |
| Bausch Health US, LLC | $79.45 | 2022-2023 | Aplenzin |
| Otsuka America Pharmaceutical, INC. | $49.16 | 2024 | Rexulti |
| Sunovion Pharmaceuticals INC. | $40.21 | 2022 | |
| Neuronetics, INC. | $36.57 | 2023 | Neurostar Tms Therapy System |
| E.R. Squibb & Sons, L.L.C. | $31.36 | 2024 | Cobenfy |
| Axsome Therapeutics, INC. | $30.42 | 2023 | Auvelity |
| Biogen, INC. | $29.67 | 2024 | Spinraza |
| Almatica Pharma LLC | $24.20 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessica Jun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.